Levosimendan

Levosimendan

• CAS Number: 141505-33-1
• UNSPSC Description: Levosimendan (Simsndan; OR-1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.
• Target Antigen: Autophagy; Phosphodiesterase (PDE); Potassium Channel
• Type: Reference compound
• Related Pathways: Autophagy;Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease
• Applications: COVID-19-immunoregulation
• Field of Research: Cardiovascular Disease
• Assay Protocol: https://www.medchemexpress.com/Levosimendan.html
• Solubility: DMSO : ≥ 50 mg/mL
• Smiles: O=C1C[C@@H](C)C(C2=CC=C(N/N=C(C#N)/C#N)C=C2)=NN1
• Molecular Weight: 280.28
• References & Citations: [1]Nieminen, M.S., et al., Levosimendan: current data, clinical use and future development. Heart Lung Vessel, 2013. 5(4): p. 227-245.|[2]Papp, Z., et al., Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol, 2012. 159(2): p. 82-7.|[3]Landoni, G., et al., Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med, 2012. 40(2): p. 634-46.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched